Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
G-5555 has a Ki of 3.7 nM, making it a strong PAK1 conjugate. Of the 235 interactions evaluated, G-5555 shown good interactions, modifying but inhibiting 8 of them by more than 70%: PAK2, PAK3, KHS1, Lck, MST3, MST4, SIK2, and YSK1. G-5555 has an IC50 of 9, 11, 10, 20, 34, 43, and 52 nM against SIK2, PAK2, KHS1, MST4, YSK1, MST3, and Lck, in that order. G-5555 generally shows good selectivity for group I PAKs. G-5555 exhibits very little action on hERG channels in patch-clamp studies, with an IC50 greater than 10 μM [1]. G-5555 inhibits PAK2 potently, having a Ki of 11 nM. G-5555 had much more growth inhibitory action in the PAK cell line than in non-amplified cell lines in a panel of 23 tumor cell lines [2].
|
---|---|
ln Vivo |
G-5555 has a deadly half-life and poor blood clearance. High oral bioavailability (F=80%) and good oral exposure (AUC=30 μM h) were attained [1]. G-5555 inhibited phosphorylation of the PAK1/2 downstream substrate mitogen-activated protein kinase 1 (MEK1) S298 in a simulator H292 non-small cell lung cancer (NSCLC) xenograft study. When given at a final dose of 25 mg hour/kg bid, this model and the PAK1 breast cancer xenograft model MDAMB-175 showed 60% tumor growth inhibition [2].
|
References |
[1]. Ndubaku CO, et al. Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety. ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6.
[2]. Rudolph J, et al. Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window. J Med Chem. 2016 Jun 9;59(11):5520-41 |
Molecular Formula |
C25H26CL2N6O3
|
---|---|
Molecular Weight |
529.4183
|
CAS # |
1648863-90-4
|
Related CAS # |
G-5555 hydrochloride
|
SMILES |
ClC1C([H])=C(C2=C([H])C([H])=C([H])C(C([H])([H])[H])=N2)C([H])=C([H])C=1C1=C([H])C2=C([H])N=C(N([H])C([H])([H])[H])N=C2N(C1=O)C([H])([H])C1([H])OC([H])([H])C([H])(C([H])([H])O1)N([H])[H].Cl[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~25 mg/mL (~50.71 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8889 mL | 9.4443 mL | 18.8886 mL | |
5 mM | 0.3778 mL | 1.8889 mL | 3.7777 mL | |
10 mM | 0.1889 mL | 0.9444 mL | 1.8889 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.